Philadelphia, PA 19129, US
CHEC PR is an organization dedicated to the development of new peptide drugs for conditions such as Alzheimer’s and Parkinson’s diseases, Multiple Sclerosis and other degenerative diseases. http://www.checpr.org/
CHEC PR has developed orally available peptide compounds for cell degeneration due to inflammation, oxidative stress or protein aggregation. The goal of the organization is to extend a large volume of animal data, showing excellent efficacy in neurodegenerative models, to the modeled human diseases. Possible lead indications for which there are proof of concept data: Multiple Sclerosis, Alzheimer’s and/or Parkinson’s Disease, Central Nervous System Injuries, and Seizure Disorders. There is very limited industry progress for the above indications. The current treatments for MS relapse are by injection with no long term benefit for neurodegeneration and disability and highly variable safety profiles. No combined anti-inflammatory or aggregate disposal therapies are presently available for neurodegenerative disorders like Alzheimer’s, Parkinson’s, or Huntington’s diseases. CHECs are unique because they target all the principal cellular pathologies in degenerative diseases (inflammation, cell death, protein aggregation) in an orally available formulation.
Company advisors are Timothy Cunningham, Ph.D., who discovered and isolated the compounds, and Jeffrey Greenstein, M.D., who is a neurologist/immunologist that will supervise clinical applications. The peptides are protected by issued US patents and several patent applications.
CHEC PR takes a flexible position for selection of initial lead indication and for equity sharing. Accommodating investor interest and needs in this way is expected to expedite capitalization and clinical development,
– Selection of lead indication
– IND enablement thru Phase I
Summary: CHEC PR has a highly qualified team of advisors that have developed these novel peptide therapeutics with potential is in several multi-billion dollar markets. The peptide is orally available, CNS penetrant, with no demonstrated safety concerns .
Products / Services
Novel Peptide Therapeutics
Orally available peptide compounds for cell degeneration due to inflammation, oxidative stress or protein aggregation. The organization is to extend a large volume of animal data, showing excellent efficacy in neurodegenerative models, to the modeled human diseases. Possible lead indications for which there are proof of concept data: Multiple Sclerosis, Alzheimer’s and/or Parkinson’s Disease, Central Nervous System Injuries, and Seizure Disorders.
Timothy J Cunningham and Jeffrey I Greenstein
Timothy J. Cunningham received a Ph.D. from University of Washington School of Medicine and is currently Professor of Neurobiology and Anatomy at Drexel University College of Medicine. He has conducted National Institutes of Health and private foundation supported research related to cell death and cellular repair for over 35 years, including the discovery and isolation of the parent protein and peptide fragments that are CHEC PR lead compounds.
Jeffrey I Greenstein received his medical degree from the University of Cape Town in South Africa and completed his residency in Neurology Metropolitan General Hospital in Cleveland, Ohio. Dr. Greenstein is the former Chair of Neurology, Temple University School of Medicine and currently the Director of Greenstein Neurology Associates and the Multiple Sclerosis Research Institute in Philadelphia where he continues his research on immune mechanisms that lead to the development of MS